Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338922 | 0.84 | CCR8 (0.57) | CCR8 | |
| SCHEMBL1337344 | 0.82 | CCR8 (0.56) | KMT2ATP53MEN1KDM4EMAPT | |
| SCHEMBL10889051 | 0.82 | ATM (0.50) | KMT2AMEN1HSD17B10HTT | |
| SCHEMBL1856944 | 0.76 | SLC40A1 (0.51) | KMT2ATP53KDM4EHSD17B10 | |
| SCHEMBL19748575 | 0.75 | KDR (0.81) | KMT2ATP53MEN1KDM4EKDR | |
| SCHEMBL23379789 | 0.74 | MEN1 (0.50) | KMT2AMEN1SMN1; SMN2HSD17B10HTT | |
| SCHEMBL1339803 | 0.74 | L3MBTL1 (0.46) | KMT2AMEN1SMN1; SMN2HTTCCR8 | |
| SCHEMBL12131878 | 0.73 | CCR8 (0.58) | CCR8 | |
| SCHEMBL14361046 | 0.73 | RAB9A (0.58) | KMT2ATP53MEN1MAPTSMN1; SMN2 | |
| SCHEMBL19799375 | 0.72 | KMT2A (0.73) | KMT2ATP53MEN1KDM4EKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063222-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7491827-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | KMT2A 2668/4885TP53 4047/4885MEN1 4774/4885 |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | KMT2A 2964/4885TP53 4170/4885MEN1 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.